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Background: Non-inferiority and equivalence trials require tailored methodology and therefore adequate conduct
and reporting is an ambitious task. The aim of our review was to assess whether the criteria recommended by the
CONSORT extension were followed.
Methods: We searched the Medline database and the Cochrane Central Register for reports of randomised
non-inferiority and equivalence trials published in English language. We excluded reports on bioequivalence
studies, reports targeting on other than the main results of a trial, and articles of which the full-text version was not
available. In total, we identified 209 reports (167 non-inferiority, 42 equivalence trials) and assessed the reporting
and methodological quality using abstracted items of the CONSORT extension.
Results: Half of the articles did not report on the method of randomisation and only a third of the trials were
reported to use blinding. The non-inferiority or equivalence margin was defined in most reports (94%), but was
justified only for a quarter of the trials. Sample size calculation was reported for a proportion of 90%, but the
margin was taken into account in only 78% of the trials reported. Both intention-to-treat and per-protocol analysis
were presented in less than half of the reports. When reporting the results, a confidence interval was given for 85%
trials. A proportion of 21% of the reports presented a conclusion that was wrong or incomprehensible. Overall, we
found a substantial lack of quality in reporting and conduct. The need to improve also applied to aspects generally
recommended for randomised trials. The quality was partly better in high-impact journals as compared to others.
Conclusions: There are still important deficiencies in the reporting on the methodological approach as well as on
results and interpretation even in high-impact journals. It seems to take more than guidelines to improve conduct
and reporting of non-inferiority and equivalence trials.
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With an increasing number of available effective inter-
ventions, the conduct of placebo-controlled clinical trials
is for many diseases no longer ethically justifiable. New
treatments can often not be expected to enhance the ef-
ficacy of a standard therapy. However, there are frequent
instances in which one is nevertheless interested in
evaluating a new therapy because of an expected advan-
tage other than with respect to efficacy. Non-inferiority* Correspondence: Schiller@imbi.uni-heidelberg.de
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reproduction in any medium, provided the ortrials are performed in such situations to rule out that
the treatment under investigation has unacceptably
worse efficacy than an active control standard therapy,
while superiority is acceptable or even desired. In con-
trast, it is the aim of equivalence trials to demonstrate
that the difference between the two treatments is not
large in either direction. Non-inferiority and equivalence
trials require tailored methodology and raise special
challenges with respect to design, conduct, analysis and
interpretation [1-5] As a consequence, reporting these
trials is also an ambitious task.
The CONSORT statement, which was first published
in 1996 and updated in 2001 [6] and 2010 [7], contains aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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randomised controlled clinical trials to support authors
and editors. Recent publications indicate that the report-
ing quality has somewhat improved over time and that
the CONSORT statement accounts for a substantial part
in this process [8,9]. Nevertheless, evaluation of the
reporting quality of specific trial designs indicated sub-
stantial deficits in the reporting of conduct, analysis and
results [10,11]. In a comprehensive review, Le Henanff et
al. assessed the methodological quality of 162 articles on
non-inferiority and equivalence trials published in 2003
and 2004 [10]. They found important shortcomings in
reporting of such trials and gave practical recommenda-
tions for an improvement. At the same time, an exten-
sion of the CONSORT Statement was published that
focused on the methodological aspects specific to non-
inferiority and equivalence trials with the aim of im-
proving reporting [12]. In our study, we describe how
non-inferiority and equivalence trials published after the
release of the CONSORT extension were conducted and
reported, and the extent of adherence to the CONSORT
criteria. To this end, we systematically searched and
reviewed articles on trials that aimed at demonstrating
non-inferiority or equivalence published in 2009. In an
additional analysis, we compared the results with those
previously established for trials published in 2003 and
2004 [10]. Bioequivalence studies were not included in
our investigation as they show several special features
making them different from clinical non-inferiority and
equivalence trials, such as, for example, inclusion of
healthy volunteers, application of equivalence margins
that are broadly accepted by regulating agencies and the
scientific community, disproportionately frequent use of
cross-over design, and conduct under highly standar-
dised conditions. Therefore, a number of topics assessed
in our review do not apply, or are not directly compar-
able with the situation in bioequivalence trials. Further-
more, other similar studies [10,13,14] also excluded
bioequivalence trials, and it was one of the aims of our
work to compare our results with others.
Methods
Search strategy
We used a computerised literature search of the Medline
databases and Cochrane Central Register of Controlled
Clinical Trials via Ovid SP to identify reports of rando-
mised non-inferiority and equivalence trials. We defined
the following search terms: random* AND (equivalence
OR equivalent OR noninferiority OR noninferior OR
non-inferiority OR non-inferior) and excluded the publi-
cation type Meta-Analysis, Review, and Research Sup-
port. The search was limited to citations published
between 1 January 2009 and 31 December 2009 in the
English language. The due date for the search was 6April 2010. We selected citations by screening title and
abstract to identify relevant reports. The final decision
was made on the basis of the full text. After internal har-
monisation based on the assessment of the first 25
abstracts, each of the three reviewers (PS, MN, and NB)
screened one third of the abstracts to identify the rele-
vant reports. Reasons for exclusion of citations or arti-
cles, respectively, are given in Figure 1. In case of
duplicate publications only the article that reported the
main results for the primary endpoint was selected.
Evaluation criteria and data extraction
We extracted specific criteria to examine whether
reports were prepared in compliance with the extension
of the CONSORT statement for the reporting of non-
inferiority and equivalence randomised trials [12]. This
included criteria referring to the reporting and to the
methodological quality of the trials. In addition, we
extracted general aspects to characterise the reported
trials.
The reference to the respective item described in the
CONSORT extension list and the way we abstracted
them are given in Table 1. Some of the 22 items listed in
the CONSORT extension were difficult to standardise
for extraction, or the assessment would have required
the evaluation of a number of associated trials published
elsewhere. Therefore, we decided to assess 15 derived
items that were essential in the context of non-
inferiority and equivalence, as well as feasible with re-
gard to the extraction procedure. In addition, we
assessed the interpretation given in the reports in rela-
tion to the results presented. We also checked whether
the relevant guidelines such as the CONSORT extension
for reporting of non-inferiority and equivalence rando-
mised trials [12], the revised CONSORT statement [6],
and the Points to Consider on the Choice of Noninfer-
iority Margin [15] were referenced.
In addition, we compared our results for trials pub-
lished in 2009 with the results found for non-inferiority
and equivalence trials published in 2003 and 2004, be-
fore the CONSORT extension was released [10]. In this
comparison, we looked for changes in trial characteris-
tics as well as in the adherence to criteria related to
reporting and methodological quality. For a further dif-
ferentiated assessment, we compared the quality of
reporting of trials published in four high-impact general
medical journals (JAMA, NEJM, Lancet and BMJ; selec-
tion such as in Ghimire 2012 [16]) with that of trials
published in low-impact general medical journals and in
speciality journals.
The data extraction was done by the three reviewers.
We developed a form to extract details of the selected
articles. At first, the reviewers completed data extraction
for a random sample of seven articles. All discrepancies
Figure 1 Identification of reports on non-inferiority and equivalence trials.
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was modified and the procedure was repeated. The fi-
nally agreed procedure was fixed in an instruction form
accompanying the data extraction form to improve
interobserver agreement. Interobserver agreement was
tested using a random sample of 21 articles. Each re-
viewer independently extracted data from 14 articles.
Each subset of seven articles was extracted in parallel by
one of the other two reviewers.
The data of all remaining articles were then extracted
by a single reviewer. In case of uncertainties with a spe-
cific report, a second reviewer checked the data extrac-
tion, and a solution was found by discussion.
We classified a trial as non-inferiority or equivalence
trial if the terms non-inferiority or equivalence were part
of the title or were mentioned as the aim of the trial in
the abstract. If this information was missing, the aim of
the planned analysis reported by the authors, or the kindof analysis which was actually done, was taken as an in-
dicator for the classification of the trial.
Data analysis
We calculated descriptive summary statistics for the
general and specific items stratified by the trial design.
Categorical variables were described by absolute and
relative frequency. Continuous variables were described
by the median and 25% and 75% percentiles. Differences
in trial characteristics and in adherence to reporting cri-
teria (before and after CONSORT extension, high- and
low-impact general medical journals and speciality med-
ical journals) were quantified by calculating the increase
factor based on trials per year or the absolute differences
and the associated 95% confidence intervals (CI),
respectively.
The interobserver agreement between the reviewers of
the reports was estimated for several essential criteria by
Table 1 Description of the assessment of CONSORT criteria recommended in the extension to CONSORT for non-
inferiority and equivalence trials [11] (R = reporting item, M = methodological item, I = interpretation)
CONSORT criteria Included in
present
evaluation
Category Description of assessed variables
Specify that the trial is a non-inferiority or equivalence trial Yes R Clearly identified as non-inferiority or equivalence trial in
title, abstract or full paper
Rationale for using a non-inferiority or equivalence design Yes R Justification stated for using a non-inferiority or
equivalence design
Eligibility for participants with respect to trials that established
efficacy of the reference treatment
No - -
Interventions intended for each group with respect to trials
that established efficacy of the reference treatment
No - -
Specific objectives and hypothesis concerning non-inferiority
or equivalence
Yes R Hypothesis stated clearly (text or formula)
M Margin defined
Clearly defined primary and secondary outcome measures
with respect to trials that established efficacy of the reference
treatment
(Yes) R Primary outcome identified clearly (not evaluated
whether outcome is identical to those in any trial that
established efficacy of the reference treatment)
Sample size calculation using a non-inferiority or equivalence
criterion and specifying the margin with the rationale for its
choice. When applicable, explanation of any interim analyses
and stopping rules (and whether related to a non-inferiority
or equivalence hypothesis)
Yes R Sample size calculation presented
R Elements for recalculation of sample size reported
M Margin considered
R Justification for margin stated
R Interim analyses planned
Method used to generate random allocation sequence
including details of any restriction
Yes R Method of randomisation reported
R Restriction method reported (blocking/stratification/
minimisation)
Method used to implement allocation concealment No - -
Who generated the allocation sequence and enrolled and
assigned participants
No - -
Whether participants, those administering the interventions
and those assessing the outcome were blinded to group
allocation
Yes R Method of blinding reported (any blinding; single blind,
double blind, open or double dummy design)
Statistical methods used to compare groups for primary
outcome specifying whether a 1- or 2-sided confidence
interval approach was used. Methods for additional analyses
(subgroups, adjusted analyses)
Yes R Statistical methods used for comparison reported
Participant flow through each state of the trial (diagram
strongly recommended)
Yes R Diagram of flow of participants presented
Dates defining the periods of recruitment and follow-up Yes R Dates reported
Baseline information for each group Yes R Baseline information presented for each group
Number of participants in each group included for each
analysis and whether intention-to-treat (ITT) and/or alternative
analyses were conducted
Yes R Number of participants reported - similar to 13
R Analysis sets reported
M Results of ITT and per-protocol analysis presented
For each outcome, a summary of results for each group and
the estimated effect size and its precision (useful: figure
showing confidence intervals and margins)
Yes M Results presented using a confidence interval
R Report of confidence level and 1- or 2-sided
R Report of P-value
R Figure presented
Address multiplicity by reporting any other analyses
performed
No - -
All important adverse events or side effects in each group Yes R Adverse events reported
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Table 1 Description of the assessment of CONSORT criteria recommended in the extension to CONSORT for non-
inferiority and equivalence trials [11] (R = reporting item, M = methodological item, I = interpretation) (Continued)
Interpretation of the results taking into account the non-
inferiority or equivalence hypothesis, sources of potential bias
or imprecision
Yes I Interpretation of results presented
Interpretation correct (non-inferiority/equivalence/
superiority/inferiority/inconclusive result/wrong/
incomprehensible by means of presented results)
Statement on expected advantage
Generalisability (external validity) of the trial findings No - -
General interpretation of the results in the context of current
evidence
No - -
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1.0 (statement of non-inferiority or equivalence margin
1.0 (calculation of CI according to Fleiss not possible), jus-
tification of margin 0.54 (95% CI 0.17 to 0.59), sample size
calculation based on a margin of 0.61 (95% CI 0.32 to 0.9),
report of both per-protocol (PP) and intention-to-treat
(ITT) analysis 0.27 (95% CI 0.16 to 0.38), presentation of
the CI for the difference between treatment groups of
0.61 (0.32 to 0.9).
All analyses were carried out with the software SAS
version 9.2 (SAS Institute Inc., Cary, NC, USA).Table 2 Characteristics of reports of randomised non-inferior
All trials (n = 209)
Journal type:
General medical journal 80 (38)
Speciality journal 129 (62)





Inclusion of a placebo arm 25 (12)
To show non-inferiority or equivalence of 10 (5)
1 or 2 experimental treatments v placebo
To show superiority of 1 or 2 treatments 11 (5)
compared by non-inferiority or equivalence
analysis
Sample size
Median per trial (IQR) 338 (174, 686)
Comparison
Different treatments* 142 (68)
Same treatments* 80 (38)
Two strategies 49 (23)
Two doses 27 (13)
Two durations 5 (2)
Results are presented as number (%) unless stated otherwise. *Multiple answers poResults
Identification of reports
The literature search provided a total of 869 citations. A
subset of 294 potentially relevant articles was identified
by screening the titles and abstracts. After reviewing the
full text articles we identified 209 primary reports; of
these 167 (80%) were non-inferiority trials, and 42 (20%)
were equivalence trials. The flowchart (Figure 1) gives
an overview of the selection process. The most frequent
causes for exclusion from the analysis were that the trial
was not a non-inferiority or equivalence trial and wasity and equivalent trials published in 2009
Trial type
Non-inferiority (n = 167) Equivalence (n = 42)
68 (41) 12 (29)
99 (59) 30 (71)
130 (78) 33 (79)
26 (16) 5 (12)
11 (7) 4 (10)
22 (13) 3 (7)
8 (5) 2 (5)
10 (6) 1 (2)
379 (202, 714) 198 (90, 424)
121 (73) 21 (50)
59 (35) 21 (50)
32 (19) 17 (41)
24 (14) 3 (7)
3 (2) 2 (5)
ssible, IQR: interquartile range.
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mentioning the terms ‘equivalence’ and ‘random’ in a
different context, or for descriptive purpose only.Characteristics of reports
Table 2 provides information on characteristics of the
non-inferiority and equivalence trials included in the
analysis. Eighty reports (38%) were published in general
medical journals and 129 reports (62%) in speciality
journals. More than three-quarters of the trials compared
two treatment groups. Thirty-one trials (15%) investigated
three groups and only 15 (7%) investigated four groups.
Twenty-five trials (12%) included a placebo arm to show
non-inferiority or equivalence of one or two experimental
treatments versus placebo (ten), to show superiority of
one or two treatments compared by non-inferiority or
equivalence analysis (eleven) or to investigate another ob-
jective (four).
Two-thirds of the reports (n = 142, 68%) dealt with trials
that investigated different modalities of treatments. Eighty
reports were of trials comparing the same pharmacological
treatments but using different strategies (n = 49, 23%),
doses (n = 27, 13%) or treatment durations (n = 5, 2%).
Due to trials with more than two groups, some reports re-
ferred to the investigation of different as well as the same
treatment types (n = 13, 6%). Five reports described trials
with a cross-over design (2%).
In 104 of the trials reported, a binary endpoint was
chosen as the primary endpoint (50%). A continuous
endpoint was investigated in 90 reports (43%) and a
time-to-event endpoint in 15 reports (7%).
The median number of patients randomised per trial
was 338 (25th to 75th percentiles 174 to 686). Non-
inferiority trials had a higher sample size than equiva-
lence trials with 379 (202 to 714) v 198 (90 to 424).Reporting quality
Table 3 shows the percentage of non-inferiority and
equivalence trials that met the criteria recommended in
the CONSORT extension related to reporting and me-
thodological quality as well as the assessment of the
conclusion given by the authors. Just over half of the arti-
cles gave information on the method of randomisation
(n = 115, 55%), whereas 190 articles reported on the
method of blinding (91%). Almost half the reports were
stated as double blind (43%), and more than one-third
were described as open label (37%). Dates defining the
period of recruitment were frequently presented (62%),
but dates defining the period of follow up were only
given in 10% of the reports. The flow of participants
through the trial was presented in 146 (70%) of the re-
ports with more non-inferiority trials than equivalence
trials (73% v 57%) following this recommendation.The majority of reports provided baseline information
for each group (96%). In reports on equivalence trials
the percentage was only slightly lower than in reports on
non-inferiority trials (93% v 97%). Adverse events were
presented in three-quarters of reports with a far higher
percentage for non-inferiority trials (80%) than for
equivalence trials (62%).
The criteria that are particularly important for non-
inferiority and equivalent trials in relation to reporting
quality were only followed in part. Most of the reported
trials could be identified as non-inferiority or equiva-
lence trial based on title or abstract (84%), but justifica-
tion for the design (48%) or a clear hypothesis (50%) was
only stated in half of the reports. Justification for the
choice of the non-inferiority or equivalent margin was
given in only 24% of reports. The majority of reports
(94%) identified a clear primary endpoint, gave informa-
tion regarding the sample size calculation (90%) and the
statistical methods used for the group comparison (94%)
as well as the analysis sets (90%). Mostly, the percentage
of non-inferiority trials meeting the respective criteria
was higher than the percentage of equivalence trials. An
exception was the justification for the margin which was
stated more often in reports for equivalence trials than
for non-inferiority trials (31% v 23%).
Methodological quality
The evaluation of the criteria related to methodological
quality showed a high percentage of reports defining the
non-inferiority or equivalence margin (96% v 86%). The
defined margin was taken into account in the sample size
calculation in 81% of the non-inferiority trials and 64% of
the equivalence trials. Eighty-five reports presented
results using a CI, but only 16% gave a graphical display
of the CI together with the margin as recommended.
Less than half of the reports (42%) stated the results of
the ITT as well as the PP analysis; more non-inferiority
trials than equivalence met this criterion (44% v 31%).
All reports presented an interpretation of the trial
results. The conclusion drawn by the authors was com-
prehensible and accurate in 165 reports (79%). The as-
sessment showed a higher percentage of non-inferiority
trials than equivalence trials giving a correct interpret-
ation (81% v 71%). In total, the interpretation was wrong
in 14 reports (7%), and in 30 reports (14%) it was incom-
prehensible in the light of the results presented. The
percentage of equivalence trials presenting an incompre-
hensible conclusion was considerably higher than in
non-inferiority trials (43% v 13%). A third of the reports
(34%) gave a more detailed statement, on which advan-
tage was to be expected as compensation for a poten-
tial although irrelevant inferiority. In 52 reports (25%)
this statement could be confirmed by the trial results.
However, the reported advantage could frequently not








Criteria related to reporting quality generally important for randomised trials
Method of randomisation reported 115 (55) 94 (56) 21 (50)
Restriction method reported
Blocking 59 (28) 45 (27) 14 (33)
Stratification 88 (42) 73 (44) 15 (36)
Minimisation 11 (5) 10 (6) 1 (2)
Method of blinding reported 190 (91) 152 (91) 38 (91)
Single blind 23 (11) 18 (11) 5 (12)
Double blind 90 (43) 73 (44) 17 (41)
Not blinded 77 (37) 61 (37) 16 (38)
Double dummy design 39 (19) 35 (21) 4 (10)
Blinding of administrators reported 30 (14) 26 (16) 4 (10)
Blinding of outcome assessor reported 57 (27) 46 (28) 11 (26)
Dates defining period of patient recruitment 130 (62) 104 (62) 26 (62)
Dates defining period of follow-up reported 20 (10) 16 (10) 4 (10)
Flow of participants presented as diagram 146 (70) 122 (73) 24 (57)
Baseline information presented for each group 201 (96) 162 (97) 39 (93)
Adverse events reported 159 (76) 133 (80) 26 (62)
Criteria related to reporting quality particularly important for non-inferiority and equivalence trials
Clearly identified as non-inferiority or equivalence trial in title or abstract 175 (84) 139 (83) 36 (86)
Justification for using non-inferiority or equivalence design reported 101 (48) 80 (48) 21 (50)
Hypothesis stated clearly (text or formula) 104 (50) 85 (51) 19 (45)
Primary outcome identified clearly 196 (94) 159 (95) 37 (88)
Sample size calculation reported 187 (90) 151 (90) 36 (86)
All elements for recalculation of sample size reported 124 (59) 104 (62) 20 (48)
Justification of margin reported 51 (24) 38 (23) 13 (31)
Justification of margin reported by
statistical considerations only 5 (2) 4 (2) 1 (2)
Justification of margin reported by clinical considerations only 31 (15) 23 (14) 8 (19)
Justification of margin reported by statistical as well as clinical considerations or results of a previous
study
15 (7) 11 (7) 4 (10)
Statistical methods used for comparison reported 184 (88) 149 (89) 35 (83)
Analysis sets reported 188 (90) 156 (93) 32 (76)
Criteria related to methodological quality of non-inferiority and equivalence trials
Non-inferiority or equivalence margin defined 197 (94) 161 (96) 36 (86)
Sample size taking into account the margin 163 (78) 136 (81) 27 (64)
Results reported using confidence interval 177 (85) 142 (85) 35 (83)
Figure showing confidence intervals and margins 34 (16) 24 (14) 10 (24)
Both per-protocol and ITT/modified ITT reported 87 (42) 74 (44) 13 (31)
Interpretation of results given in the reports
Interpretation referring to results presented
Comprehensible and accurate 165 (79) 135 (81) 30 (71)
Wrong 14 (7) 11 (7) 3 (7)
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Table 3 Compliance with criteria for reporting and methodology for non-inferiority and equivalence trials presented as
number (%) (Continued)
Incomprehensible 30 (14) 21 (13) 9 (21)
Statement on expected advantage 70 (34) 59 (35) 11 (26)
Expected advantage confirmed by results 52 (25) 46 (28) 6 (14)
ITT, intention-to-treat.
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tion given in the report (for example, actual reduction
of costs).
Relevant guidelines were quoted only rarely. The
CONSORT extension was quoted in 16 reports (8%).
The CONSORT Statement for randomised trials was
quoted only twice, and the Points-to-Consider-docu-
ment referring to the choice of the margin was refe-
renced only four times.
Changes in trial characteristics and quality of reporting
The comparison of our findings with the results of a
previous study published by Le Henanff et al. [10] before
the CONSORT extension was released is shown in
Table 4 and Figure 2. The previous study included 162
articles that were identified within two years (116 non-
inferiority reports, 46 equivalence reports; Table 4, Fig-
ure 2, [10]), whereas in 2009, a total of 209 articles was
identified (167 non-inferiority reports, 42 equivalence
reports). This corresponds to an increase by a factor of
2.9 for non-inferiority trials and by 1.8 for equivalence
trials published per year. Furthermore, the number of
non-inferiority or equivalence trials that included a pla-
cebo group increased from 11 trials in 2003 and 2004 to
25 trials in 2009 (increase by a factor of 4.5). With re-
gard to the type of comparison, a larger proportion of
trials in 2009 compared the same treatments (increase
by a factor of 7).
The comparison of the adherence to criteria related to
reporting quality showed changes varying considerably
across the different topics. The proportion of non-
inferiority and equivalence trials, which were clearly
identifiable in the title or abstract, decreased by 15%
from almost 100% down to 84%. The proportion of trials
described as double blind also decreased by 15% (from
58% to 43%).
The percentage of reports presenting a justification of
the defined margin continued to remain low (change
from 20% to 24%), whereas the proportion of reports
that presented a sample size calculation increased by
11%. Reports on non-inferiority trials more often showed
all elements for recalculation of the sample size (increase
by 8%), but this proportion decreased for equivalence
trials (5%).
Considering the methodological quality there was
hardly any improvement. Reports of non-inferiority trialspublished after release of the CONSORT extension more
often presented a sample size calculation taking into ac-
count the margin, as compared to reports previously
published, with an absolute change of 12% (1.4% to
21.8%). The adherence to other methodological items,
such as the defined margin presented, results of PP and
ITT analysis presented, and results presented with a CI,
showed almost no changes (absolute change in percen-
tage of adherence was between −0.1% and 3.1%). Only
the percentage of reports on non-inferiority trials com-
pliant with all four important methodological criteria
increased by 17 percentage points (6.6 to 27.5).
Reports on equivalence trials showed a more negative
picture. The adherence to the methodological criteria
decreased as compared to reports published before the
CONSORT extension. The absolute change varied be-
tween −12% and −6%. Only the proportion of reports
that were compliant with all important methodological
criteria remained stable at a level of 20%, with absolute
change of 1.9% (−15% to 18.8%).
Discussion
We investigated standard criteria regarding the reporting
and methodological quality of non-inferiority and
equivalence trials recommended in the CONSORT ex-
tension and compared our results with the results of a
previous investigation including trials reported before
the CONSORT extension was published [10,12].
The major result of our investigation was a substantial
lack of quality in reporting and conduct. Most of the
reported trials could be identified as non-inferiority or
equivalence trials based on title or abstract, but less than
half of the reports gave a rationale for the design or the
expected advantage. The non-inferiority or equivalence
margin was defined in most reports, but the majority of
reports gave no information about the justification of
the margin defined. A sample size calculation was pre-
sented in 90% of the reports, but it did not always take
the margin into account. More than half of the reports
did not present the results of ITT as well as PP analyses.
Far too many reports gave an interpretation that was
wrong or incomprehensible. Reports of equivalence trials
mostly showed a lower reporting quality than reports of
non-inferiority trials. Overall, there is no relevant im-
provement since the release of the CONSORT extension
for non-inferiority and equivalence trials. Moreover, the
Figure 2 Change of adherence to quality criteria for reporting of non-inferiority (a) and equivalence (b) trials published after release of
the CONSORT extension for non-inferiority and equivalence trials in relation to trials published before the CONSORT extension [10].
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that should be standard quality for any randomised trial.
However, this overall finding might be biased due to
an increased number of trials published in journals that
do not have a rigorous peer-review process based on
strict rules, and that do not endorse the CONSORT
statement and its extensions.
Hopewell and colleagues showed that journal endorse-
ment of CONSORT seems to be associated with
improvements in reporting of randomised trials [18].
They highlighted the need for journals to endorse the
CONSORT statement and its extensions for special
designs and to incorporate the checklists and recommen-
dations into the peer-reviewing process [18]. In 2006,
Hopewell et al. [8] found a proportion of 44% randomised
trials published in journals that endorsed CONSORT.
Later in 2008, Hopewell and colleagues [18] reported that
an even smaller proportion of a selection of high-impact
journals mentioned the general CONSORT statement in
the instructions for authors, and that only a fraction of
those journals stated that this was a requirement. More-
over, very few journals mentioned the CONSORT exten-
sion papers [18]. Since neither the present nor the
previous study determined the proportion of reports pub-
lished in CONSORT-endorsing journals, we could not
give information referring to this proportion in journals
publishing non-inferiority and equivalence trials. Instead,we stratified by impact factor and journal type and com-
pared the results for reports published in high-impact gen-
eral medical journals, in low-factor general medical
journals, and in speciality journals (see Additional file 1,
Annex). The number of non-inferiority and equivalence
trials that have been published per year increased strongly.
Here, it should be noted that reports published in special-
ity medical journals are still predominating in our investi-
gation, but the proportion is somewhat smaller than
in the previous study what might be caused by a dif-
ferent classification.
In our review we found that only a little over half the
reports gave information referring to the randomisation.
The proportion was substantially larger in high-impact
journals as compared to low-impact general medical
journals or speciality journals. Since a similar compo-
sition for the groups compared is best attained by
randomly dividing a single sample population, and ran-
domisation is a sound basic for statistical inference
[4], it should be implemented and the method should
be reported.
We found that more than half of the articles reported
blinding of the trial and more than one-third were open
label trials. Hopewell et al. [8] found a similar propor-
tion of randomised trials referring to any blinding but a
smaller proportion were reported as unblinded. How-
ever, they also found a substantial proportion of reports
Table 4 Changes of trial characteristicsa and adherenceb to criteria related to reporting and methological quality of
non-inferiority and equivalence trials reported before and after publication of the CONSORT extension
Increase factor based on trials per year (2009 to 2003/4)
Trial characteristics All trials Non-inferiority Equivalence
Number of trials reported per year 2.6 (2.1, 3.2) 2.9 (2.3, 3.7) 1.8 (1.2, 2.8)
Inclusion of a placebo arm 4.6 (2.2, 10.2) 5.5 (2.4, 14.3) 2.0 (0.3, 14.9)
Comparison of different treatments 2.0 (1.6, 2.6) 2.4 (1.8, 3.1) 1.1 (0.6, 2.0)
Comparison of same treatments 7.0 (4.3, 11.6) 8.4 (4.7, 16.4) 4.7 (2.1, 11.6)
Two strategies 6.1 (3.4, 11.5) 7.1 (3.3, 16.9) 4.9 1.9, 13.9)
Two doses 18.0 (5.5, 92.7) 24.0 (6.0, 209.5) 6.0 (0.5, 315.0)
Two durations 2.5 (0.5, 12.6) 1.3 (0.1, 11.6) 4.0 (0.2, 236.0)
Absolute change in % (95% CI) of adherence (2009 to 2003/4)
Criteria related to reporting quality All trials Non-inferiority Equivalence
Clearly identified as non-inferiority or equivalence trial in title or abstract −15.6 (−20.8, -10.5) na na
Trial described as double blind −15.0 (20.8, 10.5) −12.3 (−24.1, -0.6) −13.0 (−33.6, 7.5)
Justification of margin reported 4.0 (−4.5, 12.5) 2.1 (−7.7, 11.8) 11.4 (−6.7, 29.5)
Sample size calculation reported 11.1 (3.5, 18.7) 11.1 (2.5, 19.7) 9.6 (−6.6, 25.9)
All elements for recalculation of sample size reported 5.6 (−4.5, 15.8) 8.0 (−3.7, 19.6) −4.6 (−25.5, 16.3)
Criteria related to methodological quality
Non-inferiority or equivalence margin defined −2.0 (−6.3, 2.3) −0.1 (−4.5, 4.2) −9.9 (−22.1, 2.2)
Sample size calculation taking into account the margin 6.4 (−2.6, 15.3) 11.6 (1.4, 21.8) −11.8 (−30.8, 7.2)
Results reported using confidence interval 0.7 (−6.7, 6.2) 3.1 (−5.7, 12.0) −5.8 (−20.2, 8.6)
Both per-protocol and ITT/modified ITT-analysis reported −1.0 (−11.1, 9.2) 0.4 (−11.4, 12.1) −8.2 (−28.1, 11.7)
All 4 methodological quality criteria fulfilled 14.1 (5.1, 23.0) 17.0 (6.6, 27.5) 1.9 (−15.0, 18.8)
aIncrease factor based on trials per year (95% CI assuming Poisson counts); babsolute change in % (95% CI). ITT, intention-to-treat; na, not applicable as no
subgroup results were reported for 2003/04.
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evaluation of non-inferiority trials by Wangge et al. [14]
there one third of trials were also reported as open label.
In their review they pointed out that this was not con-
sistent with the guidelines, which recommend blinding
of any randomised trial whenever possible [4].
A diagram showing the flow of participants for each
group was presented in more than two-thirds of the
reports on non-inferiority and equivalence trials. The
subgroup of high-impact journals showed even a larger
proportion. A review on randomised trials in special
medical fields found smaller proportions [19,20]. Sur-
prisingly, Hopewell et al. [8] reported that fewer than
one third of reports of randomised trials published in
2006 included details of participant flow. Overall, with
respect to those items there seemed to be a somewhat
better reporting quality in non-inferiority and equiva-
lence trials compared to any randomised trials.
The most important specific element in planning a
non-inferiority or equivalence trial is the definition and
the method of the determination of the margin. In non-
inferiority trials the margin was reported in most of the
articles, which was much more often than in equivalence
trials. In comparison to the results of Le Henanff et al.this was no improvement, and was even a change for the
worse in equivalence trials. Only reports published in
high-impact general medical journals accomplished this
requirement in full. However, the far more important
justification of the margin was just given in a quarter of
the reports. Though this meant a small improvement
compared to the period before the release of the
CONSORT extension [12], it was far too low. Wangge et
al. reported a higher percentage of 46% of the articles
that gave the method by which the margin was deter-
mined, but this was also not sufficient [14]. This higher
percentage could be caused by the different selection of
trials the authors investigated, which excluded non-drug
trials. However, we did not find such results for trials
published in high-impact general medical journals.
Most of the reports presented information on the sam-
ple size calculation and there was some improvement in
comparison to previous studies. Although this portion
was higher in high-impact than in low-impact journals,
the more important finding was the fact that in a sub-
stantial proportion of reports the margin was not con-
sidered, and an even larger number of articles did not
report on all elements needed for a recalculation
(20% or 40%, respectively). There too, in high-impact
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to the details than in speciality or low-impact journals.
The lower quality in speciality journals was also con-
firmed by a review on non-inferiority and equivalence
trials in a specialised medical area [13].
With respect to the analysis, the guidelines state that
both ITT and PP analysis have equal importance in non-
inferiority and equivalence trials [5,12], since both ana-
lyses can be biased. However, nearly half of the reports
stated the results of both analyses, which is similar to
the percentage in the period before publication of the
CONSORT extension [10]. Trials published in high-
impact journals showed only slightly better results.
However, the overall results found by Wangge et al.
were similar, though the proportion of high-impact
journals reporting on both analysis sets was considerably
lower [14].
In most reports the results were presented with a CI
as recommended (85%). In high-impact journals this was
even true for 100% of the reports. Nevertheless, only a
fraction of reports graphically displayed the CI together
with the margin, which is the recommended and most
informative way of presenting the results with respect to
interpretation. In our investigation there were only small
differences between trials published in the different
types of journals. But in the speciality reports revie-
wed by Eyawo et al., graphical display of results was
very rare [13].
In nearly two-thirds of the reports the authors
concluded that non-inferiority or equivalence, respect-
ively, was demonstrated. Wangge et al. found a substan-
tially higher portion of the reports claiming to have
demonstrated non-inferiority (90%) [14]. Nevertheless,
more important than the respective conclusion by the
authors is whether the conclusion is confirmed by the
results presented. The percentage of reports with wrong
or incomprehensible conclusion added up to one fifth
for non-inferiority trials or even more for equivalence
trials, which is far too high. After all, many readers
gather only the primary message of a paper and will
be misled.
The strengths of our investigation were that we
assessed the complete set of reports of non-inferiority
and equivalence trials published in 2009 and identi-
fied these by a clearly defined search strategy. Hence,
the basis of our investigation is the entire picture of
published reports and considerably exceeds a more or
less representative random sample [11,14] or an ana-
lysis of trials regarding only a specific therapeutic area
[13,19-22].
In order to check the criteria most relevant for
non-inferiority and equivalence trials, we abstracted
most of the recommendations described in the
extension to the CONSORT statement for this trialtype. Furthermore, we defined all evaluation criteria
a priori and established a comprehensive review
procedure.
However, our research has also several limitations.
Due to the considerable effort we could only investigate
reports published in 2009 and we therefore had no own
investigation of another year’s set of reports for a direct
comparison. We decided to use a search strategy similar
to the one used in a previous survey published in 2006
[10] to allow a comparison with this and to investigate
the impact of the CONSORT extension. However, we
are aware of the possible bias due to the course of time
and different reviewers. This approach was limited due
to the selection of criteria reported in the previous pub-
lication [10] and did not allow the comparison of some
important items as well as a stratified comparison for
high- and low-impact general medical journals for both
years. We therefore could only present the stratified
results for reports published in 2009.
Moreover, it was not possible to standardise or ab-
stract all 22 items referred to in the CONSORT state-
ment. For example, the appropriateness of the
interventions with respect to trials that established effi-
cacy for the reference treatment is an important issue,
but this would have required the assessment of a huge
number of associated trials published elsewhere. Due to
the inclusion in our database search of the term ‘equiva-
lent’ we got a particularly high number of unspecific
results. Though each abstract was carefully examined
and questionable cases were clarified by two reviewers
using the full text, it might be possible that some further
suitable reports were not selected for the analysis.
Conclusion
There are still important deficiencies in the reporting on
the methodological approach as well as on results and
interpretation of non-inferiority and equivalence trials
even in high-impact journals. Improvement of the over-
all situation seems to require other measures than
appropriate guidelines and recommendations. It might
be helpful to facilitate a better overview and access to
the guidelines relevant for the different trial types. But it
might be more important to support researchers and
reviewers by offering specific training accompanied by
an explicit demand of a strict monitoring of CONSORT
requirements in the peer-review process. This approach
is strongly assisted by the EQUATOR-network, an inter-
national initiative that tries to improve the reliability and
value of medical research literature by promoting
transparent and accurate reporting of research studies
[23,24]. Hopefully, these comprehensive measures will
have a positive effect on the quality of reporting in
different trial types. In any case, there is an urgent need
for improvement, which is especially important against
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the past years.
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